Lake Street has significantly reduced its price target for P3 Health Partners (PIII, Financial), bringing it down from $50 to $20, while maintaining a Buy rating on the stock. Despite recent setbacks, the analyst believes that P3 could still play a crucial role in delivering cost-effective, high-quality healthcare through value-based solutions.
Acknowledging past optimism that did not align with P3's actual performance, the firm is not conceding defeat on the company's prospects. The latest adjustment reflects a strategic recalibration, particularly following a 1:50 reverse stock split intended to make PIII shares more appealing to institutional investors. The analyst underscores the potential for P3 to emerge as a substantial entity in the healthcare sector, encouraging investors to consider the stock at its new valuation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for P3 Health Partners Inc (PIII, Financial) is $37.50 with a high estimate of $50.00 and a low estimate of $12.50. The average target implies an upside of 305.84% from the current price of $9.24. More detailed estimate data can be found on the P3 Health Partners Inc (PIII) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, P3 Health Partners Inc's (PIII, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for P3 Health Partners Inc (PIII, Financial) in one year is $37.53, suggesting a upside of 306.17% from the current price of $9.24. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the P3 Health Partners Inc (PIII) Summary page.
